ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
NYSE:ADCT
Price:
4.68 USD
-0.85%
Updated:
Apr 23, 2024
ADC Therapeutics SA
Other Current Liabilities
Last
Value
3-Years CAGR
5-Years CAGR
|
ADC Therapeutics SA
Other Current Liabilities Peer Comparison
Comparables:
ACIU
CRSP
BSLN
IDIA
KURN
Competitive Other Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Other Current Liabilities
$13m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Other Current Liabilities
CHf138k
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Other Current Liabilities
$9.7m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Other Current Liabilities
CHf8.6m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-16%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Other Current Liabilities
CHf11.2m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Other Current Liabilities
CHf3.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Other Current Liabilities?
Other Current Liabilities
13m
USD
13m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Other Current Liabilities amounts to 13m USD.
What is ADC Therapeutics SA's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
4%
4%
Over the last year, the Other Current Liabilities growth was -77%. The average annual Other Current Liabilities growth rates for ADC Therapeutics SA have been -11% over the past three years , 4% over the past five years .
You don't have any saved screeners yet
